{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-121833","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.924122+00:00","generated_at":"2026-05-30T04:48:02.449726+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Coya Therapeutics Q3 net loss $4.0M, cash $39.8M post-raise; positive AD data, new CEO","bullets":["Net loss $4.0M in Q3 2024 (vs $3.4M prior); cash $31.1M (Sep) rose to $39.8M after capital raise.","Positive LD IL-2 data in mild-moderate Alzheimer's from investigator-initiated Phase 2 presented at CTAD24; patents filed for COYA 301/GLP-1 combo.","Arun Swaminathan appointed CEO effective Nov 1, 2024; Howard Berman transitions to Executive Chairman.","Aligned with FDA on non-clinical data for COYA-302 Phase 2b ALS trial; eligible for $8.4M milestone from Dr. Reddy's upon IND acceptance and dosing.","2025 catalysts: additional AD data Q1, ALS biomarker data Q2, FTD data 2H, and COYA-302 IND for FTD expected in 2H."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-121833","json":"https://secwatch.observer/filing/0000950170-24-121833.json","markdown":"https://secwatch.observer/filing/0000950170-24-121833.md","text":"https://secwatch.observer/filing/0000950170-24-121833.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000095017024121833/0000950170-24-121833-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000095017024121833/coya-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:48:02.449726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}